Mohamed Salah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Salah has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed S. Abdelsamie
ElexoPharm GmbH , Im Stadtwald, Building A1.2 , 66123 Saarbrücken , Germany
8 shared publications - Mohammad Abdel-Halim
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo
8 shared publications - Martin Frotscher
Department of Pharmaceutical and Medicinal Chemistry , Saarland University , 66123 Saarbrücken , Germany
7 shared publications - Matthias Engel
Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany
6 shared publications - Chris J. van Koppen
Department of Pharmaceutical and Medicinal Chemistry, Universitätscampus C2.3, 66123 Saarbrücken, Germany
5 shared publications - Ashraf Hassan Abadi
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt
4 shared publications
Latest Publications
- 2 May 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (6) , 1591-1609
Targeting Neutrophil-Mediated Inflammation: Identification of Pyrazolidinone Carboxamide Derivatives as Potent Selective Inhibitors of Formyl Peptide Receptor 1 (FPR1)-Activated Neutrophils
Neutrophils play a critical role in the innate immune response, but their overactivation can lead to chronic inflammation and tissue damage in conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and sepsis. Formyl peptide receptor 1 (FPR1) is a key regulator of neutrophil activation, making it an attractive target for therapeutic intervention. In this study, an in-house screening revealed pyrazolidinone carboxamide derivatives as effective inhibitors of neutrophil activation, exhibiting no cytotoxic effects. Compounds 10–12 and 21 demonstrated selective inhibition of FPR1-induced neutrophil superoxide anion production and elastase release with submicromolar IC50 values, while having no effect on the FPR2 pathway. On a structural level, electron-withdrawing groups on the thiazole ring within the amide side chain were found to be crucial for high potency. Binding assays confirmed that compounds 10, 11 and 21 act as direct antagonists of FPR1. In the LPS-induced acute respiratory distress syndrom (ARDS) model in mice, compound 10 significantly reduced pulmonary inflammation, oxidative stress, and neutrophil elastase activity, while showing no signs of toxicity in the liver or kidneys at the tested doses, highlighting its protective effects. Furthermore, molecular docking and dynamic simulations provided insights into their binding poses, explaining their interactions with key residues within the FPR1 binding site. This study lays the foundation for optimizing this class of compounds as therapeutic agents for controlling neutrophil-mediated inflammation.
- 2 May 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (6) , 1591-1609
Targeting Neutrophil-Mediated Inflammation: Identification of Pyrazolidinone Carboxamide Derivatives as Potent Selective Inhibitors of Formyl Peptide Receptor 1 (FPR1)-Activated Neutrophils
Neutrophils play a critical role in the innate immune response, but their overactivation can lead to chronic inflammation and tissue damage in conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and sepsis. Formyl peptide receptor 1 (FPR1) is a key regulator of neutrophil activation, making it an attractive target for therapeutic intervention. In this study, an in-house screening revealed pyrazolidinone carboxamide derivatives as effective inhibitors of neutrophil activation, exhibiting no cytotoxic effects. Compounds 10–12 and 21 demonstrated selective inhibition of FPR1-induced neutrophil superoxide anion production and elastase release with submicromolar IC50 values, while having no effect on the FPR2 pathway. On a structural level, electron-withdrawing groups on the thiazole ring within the amide side chain were found to be crucial for high potency. Binding assays confirmed that compounds 10, 11 and 21 act as direct antagonists of FPR1. In the LPS-induced acute respiratory distress syndrom (ARDS) model in mice, compound 10 significantly reduced pulmonary inflammation, oxidative stress, and neutrophil elastase activity, while showing no signs of toxicity in the liver or kidneys at the tested doses, highlighting its protective effects. Furthermore, molecular docking and dynamic simulations provided insights into their binding poses, explaining their interactions with key residues within the FPR1 binding site. This study lays the foundation for optimizing this class of compounds as therapeutic agents for controlling neutrophil-mediated inflammation.
- 27 June 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (13) , 8975-8992
Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model
Treating estrogen-dependent diseases like endometriosiswith drugssuppressing local estrogen activation may be superior to existingendocrine therapies. Steroid sulfatase (STS) and 17 & beta;-hydroxysteroiddehydrogenase type 1 (17 & beta;-HSD1) are key enzymes of local estrogenactivation. We describe the rational design, synthesis, and biologicalprofilation of furan-based compounds as a novel class of dual STS/17 & beta;-HSD1inhibitors (DSHIs). In T47D cells, compound 5 showedirreversible inhibition of STS and potent, reversible inhibition of17 & beta;-HSD1. It was selective over 17 & beta;-HSD2 and displayedhigh metabolic stabilities in human and mouse liver S9 fractions.No effect on cell viability was detected up to 31 & mu;M (HEK293)and 23 & mu;M (HepG2), respectively, and there was no activationof the aryl hydrocarbon receptor (AhR) up to 3.16 & mu;M. Singledaily application to mice revealed steady-state plasma levels highenough to make this compound eligible for an in vivo proof-of-principle study in a mouse endometriosis model.
- 27 June 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (13) , 8975-8992
Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model
Treating estrogen-dependent diseases like endometriosiswith drugssuppressing local estrogen activation may be superior to existingendocrine therapies. Steroid sulfatase (STS) and 17 & beta;-hydroxysteroiddehydrogenase type 1 (17 & beta;-HSD1) are key enzymes of local estrogenactivation. We describe the rational design, synthesis, and biologicalprofilation of furan-based compounds as a novel class of dual STS/17 & beta;-HSD1inhibitors (DSHIs). In T47D cells, compound 5 showedirreversible inhibition of STS and potent, reversible inhibition of17 & beta;-HSD1. It was selective over 17 & beta;-HSD2 and displayedhigh metabolic stabilities in human and mouse liver S9 fractions.No effect on cell viability was detected up to 31 & mu;M (HEK293)and 23 & mu;M (HepG2), respectively, and there was no activationof the aryl hydrocarbon receptor (AhR) up to 3.16 & mu;M. Singledaily application to mice revealed steady-state plasma levels highenough to make this compound eligible for an in vivo proof-of-principle study in a mouse endometriosis model.
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 227, 113911
Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 227, 113911
Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects
- 1 February 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 172, 113781
Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis
- 1 February 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 172, 113781
Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis
- 1 September 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 178, 93-107
Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation
- 1 September 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 178, 93-107
Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (15) , 7289-7301
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), may be more efficacious in the treatment of osteoporosis. Blockade of 17β-HSD2 is thought to increase intracellular estradiol and testosterone in bone, thereby inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, respectively. We here describe the design, synthesis, and biological characterization of a novel bicyclic-substituted hydroxyphenylmethanone 17β-HSD2 inhibitor (compound 24). Compound 24 is a nanomolar potent inhibitor of human 17β-HSD2 (IC50 of 6.1 nM) and rodent 17β-HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor α affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model. Administration of 24 in a rat osteoporosis model demonstrates its bone-sparing efficacy.
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (15) , 7289-7301
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), may be more efficacious in the treatment of osteoporosis. Blockade of 17β-HSD2 is thought to increase intracellular estradiol and testosterone in bone, thereby inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, respectively. We here describe the design, synthesis, and biological characterization of a novel bicyclic-substituted hydroxyphenylmethanone 17β-HSD2 inhibitor (compound 24). Compound 24 is a nanomolar potent inhibitor of human 17β-HSD2 (IC50 of 6.1 nM) and rodent 17β-HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor α affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model. Administration of 24 in a rat osteoporosis model demonstrates its bone-sparing efficacy.
- Open Access
- 1 June 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 489, 66-81
Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges
- 1 June 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 489, 66-81
Open AccessInhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges
- 15 January 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (3) , 1362-1372
Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition of steroidogenic enzymes may pose an attractive alternative with much less side effects. Here, we describe the design of a nanomolar potent 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitor (compound 15) and successful targeted intracrine therapy in a mouse bone fracture model. Blockade of 17β-HSD2 in bone is thought to increase intracellular estradiol (E2) and testosterone (T), which thereby inhibits bone resorption by osteoclasts and stimulates bone formation by osteoblasts, respectively. Administration of compound 15 in the mouse fracture model strongly increases the mechanical stability of the healing fractured bone because of a larger periosteal callus with newly formed bone without changing the plasma E2 and T concentrations. Steroidogenic 17β-HSD2 inhibition thus enables targeted intracrine therapy.
- 15 January 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (3) , 1362-1372
Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition of steroidogenic enzymes may pose an attractive alternative with much less side effects. Here, we describe the design of a nanomolar potent 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitor (compound 15) and successful targeted intracrine therapy in a mouse bone fracture model. Blockade of 17β-HSD2 in bone is thought to increase intracellular estradiol (E2) and testosterone (T), which thereby inhibits bone resorption by osteoclasts and stimulates bone formation by osteoblasts, respectively. Administration of compound 15 in the mouse fracture model strongly increases the mechanical stability of the healing fractured bone because of a larger periosteal callus with newly formed bone without changing the plasma E2 and T concentrations. Steroidogenic 17β-HSD2 inhibition thus enables targeted intracrine therapy.